Company intelligence / Profile preview
Passage Bio
Philadelphia, Pennsylvania, United Statespassagebio.com ↗
- Ownership
- Public · PASG
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Passage Bio's lead candidate PBFT02 has shown promising initial safety and biomarker data in the Phase 1/2 upliFT-D clinical trial for frontotemporal dementia with GRN mutations. The therapy has demonstrated consistent, durable increases in CSF progranulin levels with a well-tolerated safety profile[6][10].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Gene therapyAAV-delivery gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
University of Pennsylvania's Gene Therapy Program (GTP)InformedDNA
04
Financials
- Market cap
- $11.1M
- Total revenue
- $0
- Enterprise value
- $-13M
Beyond the preview
Go deeper on Passage Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Passage Bio.